Medicare Part D coverage · 24 · RxCUI 1805427
24 HR donepezil hydrochloride 10 MG / memantine hydrochloride 7 MG Extended Release Oral Capsule [Namzaric]
Per the CMS 2026 Part D formulary file, 24 HR donepezil hydrochloride 10 MG / memantine hydrochloride 7 MG Extended Release Oral Capsule [Namzaric] is covered by 1,959 Medicare Part D plans (38.8% of enrollable products), averaging Tier 3.3, with prior authorization required on 3.5% of covering formularies.
- 38.8%
- Plan coverage
- 1,959
- Plans covering
- T3.3
- Avg tier
- 3.5%
- Prior auth required
What the CMS Formulary Data Shows for 24 HR donepezil hydrochloride 10 MG / memantine hydrochloride 7 MG Extended Release Oral Capsule [Namzaric]
Per the CMS 2026 Part D formulary file, 24 HR donepezil hydrochloride 10 MG / memantine hydrochloride 7 MG Extended Release Oral Capsule [Namzaric] (RxNorm concept RXCUI 1805427, generic name 24) appears on 113 distinct formulary files spanning 1,959 Medicare Part D plan offerings - 38.8% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 3.3.
Real-world access to 24 HR donepezil hydrochloride 10 MG / memantine hydrochloride 7 MG Extended Release Oral Capsule [Namzaric] depends on utilization management as much as tier placement: 3.5% of covering formularies require prior authorization. 8.8% require step therapy. 13.3% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 21,609 Part D beneficiaries filled 24 HR donepezil hydrochloride 10 MG / memantine hydrochloride 7 MG Extended Release Oral Capsule [Namzaric] in 2023, with total plan-and-beneficiary spending of $107,814,107 and an average per-beneficiary annual cost of $4,989.31. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry 24 HR donepezil hydrochloride 10 MG / memantine hydrochloride 7 MG Extended Release Oral Capsule [Namzaric] today.
Coverage Details
- Formularies covering
- 113
- Plans covering
- 1,959
- Coverage rate
- 38.8%
- Tier range
- Tier 1 – Tier 4
- Average tier
- Tier 3, Preferred Brand
Restrictions
- Prior authorization required
- 3.5% of formularies
- Step therapy required
- 8.8% of formularies
- Quantity limits
- 13.3% of formularies
2023 Medicare Spending
- Beneficiaries
- 21,609
- Total spending
- $107,814,107
- Avg per beneficiary
- $4,989.31
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering 24 HR donepezil hydrochloride 10 MG / memantine hydrochloride 7 MG Extended Release Oral Capsule [Namzaric]
100 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| Florida Complete Care-Duals VIP (HMO-POS D-SNP) | Hpmp OF Florida, Inc. | T1 | No | $0 | FL |
| Mercy Care Advantage (HMO D-SNP) | Mercy Care | T1 | No | $0 | AZ |
| Mercy Care Advantage (HMO D-SNP) | Mercy Care | T1 | No | $0 | AZ |
| Mercy Care Advantage (HMO D-SNP) | Mercy Care | T1 | No | $0 | AZ |
| Elderplan Plus Long-Term Care (HMO-POS D-SNP) | Elderplan, Inc. | T1 | No | $0 | NY |
| Health Choice Pathway (HMO D-SNP) | Health Choice Arizona, Inc. | T1 | No | $0 | AZ |
| Healthfirst CompleteCare (HMO D-SNP) | Healthfirst Health Plan, Inc. | T1 | No | $0 | NY |
| IMCare Classic (HMO D-SNP) | Itasca Medical Care | T1 | No | $0 | MN |
| Johns Hopkins Advantage MD D-SNP (HMO D-SNP) | Hopkins Health Advantage, Inc. | T1 | No | $0 | MD |
| MetroPlus UltraCare (HMO D-SNP) | Metroplus Health Plan, Inc. | T1 | No | $0 | NY |
| Senior Whole Health SCO (HMO D-SNP) | Senior Whole Health, LLC | T1 | No | $0 | MA |
| Senior Whole Health SCO NHC (HMO D-SNP) | Senior Whole Health, LLC | T1 | No | $0 | MA |
| Molina One Care (HMO D-SNP) | Senior Whole Health, LLC | T1 | No | $0 | MA |
| NaviCare (HMO D-SNP) | Fallon Community Health Plan | T1 | No | $0 | MA |
| SeniorCare Complete (HMO D-SNP) | South Country Health Alliance | T1 | No | $0 | MN |
| AbilityCare (HMO D-SNP) | South Country Health Alliance | T1 | No | $0 | MN |
| Alameda Alliance Wellness (HMO D-SNP) | Alameda Alliance FOR Health | T1 | No | $0 | CA |
| CCA One Care (HMO D-SNP) | Commonwealth Care Alliance, Inc. | T1 | No | $0 | MA |
| CCA Senior Care Options (HMO D-SNP) | Commonwealth Care Alliance, Inc. | T1 | No | $0 | MA |
| Community Care's Partnership Program (HMO D-SNP) | Community Care Health Plan, Inc. | T1 | No | $0 | WI |
Show the next 30 plans
Showing top 50 of 100 plans.
Frequently Asked Questions
Is 24 HR donepezil hydrochloride 10 MG / memantine hydrochloride 7 MG Extended Release Oral Capsule [Namzaric] covered by Medicare Part D?
Yes, 24 HR donepezil hydrochloride 10 MG / memantine hydrochloride 7 MG Extended Release Oral Capsule [Namzaric] is covered by 1,959 Medicare Part D plans (38.8% of all Part D formularies).
What tier is 24 HR donepezil hydrochloride 10 MG / memantine hydrochloride 7 MG Extended Release Oral Capsule [Namzaric] on Medicare Part D plans?
24 HR donepezil hydrochloride 10 MG / memantine hydrochloride 7 MG Extended Release Oral Capsule [Namzaric] averages Tier 3.3 across Part D plans, ranging from Tier 1 to Tier 4.
Does 24 HR donepezil hydrochloride 10 MG / memantine hydrochloride 7 MG Extended Release Oral Capsule [Namzaric] require prior authorization?
3.5% of Part D formularies require prior authorization for 24 HR donepezil hydrochloride 10 MG / memantine hydrochloride 7 MG Extended Release Oral Capsule [Namzaric]. Step therapy: 8.8%. Quantity limits: 13.3%.
How much does Medicare spend on 24 HR donepezil hydrochloride 10 MG / memantine hydrochloride 7 MG Extended Release Oral Capsule [Namzaric]?
In 2023, total Medicare Part D spending on 24 HR donepezil hydrochloride 10 MG / memantine hydrochloride 7 MG Extended Release Oral Capsule [Namzaric] was $107,814,107, covering 21,609 beneficiaries. The average spend per beneficiary was $4,989.31.
Read our methodology - how this data is sourced, computed, and verified.
Nationwide similar Part D drugs
Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.
Closest average formulary tier
- 72 HR fentanyl 0.0875 MG/HR Transdermal System T3.3
- Preservative-Free timolol 2.5 MG/ML Ophthalmic Solution T3.3
- opicapone 25 MG Oral Capsule [Ongentys] T3.3
- tretinoin 0.5 MG/ML Topical Lotion [Altreno] T3.3
- buprenorphine 2 MG / naloxone 0.5 MG Sublingual Film [Suboxone] T3.3
- 0.5 ML ustekinumab-ttwe 90 MG/ML Prefilled Syringe T3.3
Similar prior-authorization rate
- 84 HR estradiol 0.00156 MG/HR Transdermal System 3.5% PA
- BX Rating 24 HR methylphenidate hydrochloride 18 MG Extended Release Oral Tablet 3.5% PA
- ethinyl estradiol 0.0025 MG / norethindrone acetate 0.5 MG Oral Tablet [Fyavolv] 3.4% PA
- insulin, regular, human 100 UNT/ML Injectable Solution [Humulin R] 3.4% PA
- prochlorperazine 10 MG Oral Tablet 3.7% PA
- 1.5 ML aripiprazole 200 MG/ML Prefilled Syringe [Abilify] 3.7% PA